Sivelestat and Incidence of Acute Respiratory Distress Syndrome After Cardiovascular Surgery: A Randomized Clinical Trial - PubMed
2 days ago
- #cardiovascular surgery
- #sivelestat
- #ARDS
- Sivelestat, a neutrophil elastase inhibitor, was tested in a randomized clinical trial for reducing ARDS incidence post-cardiovascular surgery.
- The study involved 424 participants undergoing various cardiovascular procedures, with 382 completing the trial.
- Participants received either sivelestat or placebo immediately post-surgery, continuing for up to 7 days or until ICU discharge.
- Primary outcome was ARDS incidence, with secondary outcomes including inflammatory biomarkers and ARDS-related clinical outcomes.
- Sivelestat group showed significantly lower ARDS rates (16.8% vs 31.2%) and reduced 90-day mortality (1.1% vs 5.2%).
- Inflammatory biomarkers like neutrophil elastase and interleukin 6 were notably lower in the sivelestat group.
- The findings suggest sivelestat may effectively mitigate ARDS and reduce mortality in cardiovascular surgery patients.